title: Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain.
abstract: Although blood pressure (BP) control is crucial in hypertensive patients, clinical practice guidelines agree that the goal of treatment should be aimed at not only decreasing BP but reducing global cardiovascular risk. The aim of this cross-sectional study was to evaluate BP, low-density lipoprotein cholesterol (LDL-C), and composite control rates in a hypertensive population in a primary care setting in Spain. Good BP control was defined as <140/90 mm Hg (<130/80 mm Hg for diabetics).LDL-C control rate was established according to the third report of the National Cholesterol Education Program Adult Treatment Panel criteria. A total of 12,954 patients (49.9% women, aged 62.1+/-10.7 years) were included. BP was controlled in 24.8% of patients, LDL-C in 26% of patients and, when combined, in only 8.6%. The rates of control were significantly worse in high-risk subgroups, such as high-coronary-risk, diabetic, or metabolic syndrome patients. The BP and LDL-C control rates in the hypertensive population attended to daily in primary care settings in Spain are low.
authors.affiliation: Department of Cardiology, Hospital Rámon y Cajal, Madrid, Spain. vbarriosa@meditex.es
authors.forename: Vivencio
authors.initials: V
authors.lastname: Barrios
authors.forename: Carlos
authors.initials: C
authors.lastname: Escobar
authors.forename: Alberto
authors.initials: A
authors.lastname: Calderón
authors.forename: José L
authors.initials: JL
authors.lastname: Llisterri
authors.forename: Rocio
authors.initials: R
authors.lastname: Echarri
authors.forename: Eduardo
authors.initials: E
authors.lastname: Alegría
authors.forename: Javier
authors.initials: J
authors.lastname: Muñiz
authors.forename: Arantxa
authors.initials: A
authors.lastname: Matalí
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood* / Q000187:drug effects; D003430:Cross-Sectional Studies; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011320:Primary Health Care; D012107:Research Design; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D049629:Waist-Hip Ratio
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides